Nplate (romiplostim) - Important Safety Information from Amgen as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 26/01/2011


Problem Or Issue:

Important safety information communication from Amgen on revised dose adjustment in ITP patients and warnings for use in ITP patients with hepatic impairment.

Important Safety Information - Nplate (romiplostim)

« Back